Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients
3期
已完成
NCT04737187
| 适应症 | Refractory Metastatic Colorectal Cancer |
|---|
| 分期 | 3期 |
|---|
| 申办方 | Taiho Oncology, Inc. |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 492 人 |
|---|
| 干预（药物） | Trifluridine/Tipiracil, Bevacizumab |
|---|
| 开始日期 | 2020年11月25日 |
|---|
| 完成日期 | 2022年7月19日 |
|---|
| 结果公布日 | 2023年12月26日 |
|---|
摘要
This study is designed as an international, open-label, controlled two-arm, randomized phase III comparison study evaluating the efficacy and safety of trifluridine/tipiracil in combination with bevacizumab versus trifluridine/tipiracil monotherapy in patients with refractory mCRC.
Overall Survival (OS)
From date of randomization to the death due to any cause or cut-off date, whichever comes first (maximum duration: up to 20 months) · months
| Trifluridine/Tipiracil + Bevacizumab | 10.78 months |
|---|
| Trifluridine/Tipiracil | 7.46 months |
|---|
| p-value | < 0.001 |
|---|
| Hazard Ratio (HR) | 0.61 (95% CI 0.49–0.77) |
|---|
Survival Probability at 6 Months
From date of randomization until 6 months post treatment · probability of participants
| Trifluridine/Tipiracil + Bevacizumab | 0.77 probability of participants |
|---|
| Trifluridine/Tipiracil | 0.61 probability of participants |
|---|
Survival Probability at 12 Months
From date of randomization until 12 months post treatment · probability of participants
| Trifluridine/Tipiracil + Bevacizumab | 0.43 probability of participants |
|---|
| Trifluridine/Tipiracil | 0.30 probability of participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。